Chunyi Hao
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
- Oncology 48
- Pancreatic and Hepatic Oncology Research 23
- Cancer Cells and Metastasis 7
- Cancer Immunotherapy and Biomarkers 7
- Peptidase Inhibition and Analysis 6
-
- Sarcoma Diagnosis and Treatment 29
- Co-authors
- Xiuyun Tian (68 shared papers)Xiaoya Guan (28 shared papers)Jianhui Wu (45 shared papers)Ang Lv (42 shared papers)Min Zhao (16 shared papers)Hong-Gang Qian (21 shared papers)Yan Liang (15 shared papers)Bin Dong (13 shared papers)
- Journals
- Journal of Clinical Oncology (10 papers)BioScience Trends (6 papers)International Journal of Medical Sciences (4 papers)Frontiers in Oncology (4 papers)PLoS ONE (3 papers)
- Partner nations
- ChinaEthiopiaUnited States
In The Last Decade
Chunyi Hao
128 papers receiving 2.2k citations
Chunyi Hao's Hit Papers
Peers
Comparison fields: 5 of 106
- Hepatology 391
- Oncology 684
- Cancer Research 260
- Gastroenterology 59
- Pulmonary and Respiratory Medicine 347
Countries citing papers authored by Chunyi Hao
This map shows the geographic impact of Chunyi Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunyi Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunyi Hao more than expected).
Fields of papers citing papers by Chunyi Hao
This network shows the impact of papers produced by Chunyi Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunyi Hao. The network helps show where Chunyi Hao may publish in the future.
Co-authors
The 25 scholars most cited alongside Chunyi Hao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 138 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 213 | |
| 2 | Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2022 | 130 |
| 3 | 2004 | 117 | |
| 4 | 2022 | 105 | |
| 5 | 2019 | 100 | |
| 6 | 2019 | 99 | |
| 7 | 2013 | 88 | |
| 8 | 2022 | 81 | |
| 9 | 2016 | 45 | |
| 10 | 2019 | 42 | |
| 11 | 2014 | 41 | |
| 12 | 2019 | 37 | |
| 13 | 2006 | 34 | |
| 14 | 2015 | 33 | |
| 15 | 2013 | 33 | |
| 16 | 2012 | 31 | |
| 17 | 2013 | 29 | |
| 18 | 2016 | 29 | |
| 19 | 2008 | 26 | |
| 20 | 2005 | 26 |
About Chunyi Hao
Chunyi Hao is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Surgery and Hepatology, having authored 138 papers that have together received 2.2k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (29 papers), Pancreatic and Hepatic Oncology Research (23 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Cells and Metastasis (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Peptidase Inhibition and Analysis (6 papers), Gastrointestinal Tumor Research and Treatment (6 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Hepatology (391 citations), Oncology (684 citations), Cancer Research (260 citations), Gastroenterology (59 citations) and Pulmonary and Respiratory Medicine (347 citations). Chunyi Hao has collaborated with scholars based in China, Ethiopia and United States. Frequent co-authors include Xiuyun Tian, Xiaoya Guan, Jianhui Wu, Ang Lv, Min Zhao, Hong-Gang Qian, Yan Liang, Bin Dong, Jiafu Ji and Hui Qiu. Their work appears in journals such as Journal of Clinical Oncology, BioScience Trends, International Journal of Medical Sciences, Frontiers in Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.